Hexatrione Injection, Suspension
Product Images NDC 59137-570

29 FDA label images from Medexus Pharma, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Hexatrione (NDC 59137-570). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medexus Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dhcp Page 1 (Hexatrione Dhcp 09 15 2026 With Pi Page 01)

Dhcp Page 1 (Hexatrione Dhcp 09 15 2026 With Pi Page 01)
A letter dated Sept 15, 2026, from Medexus Pharma addressing healthcare professionals about the temporary importation of Hexatrione 2% (triamcinolone hexacetonide) injectable suspension, 40 mg/2mL intra-articular ampoule, to address supply shortage. It explains coordination with the FDA for importation, details packaging of a 2 mL ampoule per carton with NDC 59137-570-01, and highlights differences from the FDA-approved Aristospan product, including labeling, absence of barcode, and equal concentration of active substance.*
FDA Label Image

Dhcp P2 (Hexatrione Dhcp 09 15 2026 With Pi Page 02 V1)

Dhcp P2 (Hexatrione Dhcp 09 15 2026 With Pi Page 02 V1)
Text document from Medexus Pharma describing Hexatrione 2% (triamcinolone hexacetonide) injectable suspension. It covers product appearance, needle recommendations, ampoule type, ordering information including required order details and contact emails, and encourages reporting of adverse events. The text emphasizes no dilution before injection and provides needle gauge guidance for intra-articular use.*
FDA Label Image

Dhcp P3 (Hexatrione Dhcp 09 15 2026 With Pi Page 03)

Dhcp P3 (Hexatrione Dhcp 09 15 2026 With Pi Page 03)
A letter from Medexus Pharma, Inc. providing instructions for reporting adverse events, medication errors, or quality problems with the product. It includes contact methods for FDA’s MedWatch Adverse Reporting Program online, by mail, or fax. The letter is signed by Khaled M Mohamed, Sr. Director of Global Regulatory Affairs and Pharmacovigilance.*
FDA Label Image

Dhcp P4 (Hexatrione Dhcp 05 26 2026 Page 04)

Dhcp P4 (Hexatrione Dhcp 05 26 2026 Page 04)
A product comparison table from Medexus Pharma comparing the US approved product Aristospan (Triamcinolone Hexacetonide Injectable Suspension, USP) with the imported product Hexatrione 2% (triamcinolone hexacetonide injectable suspension). The table details dosage forms, strengths (20 mg/mL for Aristospan and 40 mg/2mL or 20 mg/mL for Hexatrione), formulations, container closure systems, and route of administration (intra-articular) along with a summary of indications and usage for both products.*
FDA Label Image

Dhcp P5 (Hexatrione Dhcp 05 26 2026 Page 05)

Dhcp P5 (Hexatrione Dhcp 05 26 2026 Page 05)
Text panel providing dosage and administration instructions stating Hexatrione 2% should not be diluted before injection. Description notes it is a milky white injectable suspension without crystalline formation. Storage conditions recommend below 30°C and protection from light. How supplied section lists NDC 59137-570-01 as a 2 mL ampoule from Medexus Pharma, Inc.*
FDA Label Image

Dhcp P6 (Hexatrione Dhcp 05 26 2026 Page 06)

Dhcp P6 (Hexatrione Dhcp 05 26 2026 Page 06)
Packaging label image showing a vial of Aristospan injectable suspension with triamcinolone hexacetonide 20 mg/mL. The vial has a pink cap and metal seal, and the label indicates it is for intra-articular use, not intravenous use, and is Rx only. The image also includes label graphics and barcode information with manufacturing details by Sandoz Canada, Inc.*
FDA Label Image

Dhcp P7 (Hexatrione Dhcp 05 26 2026 Page 07)

Dhcp P7 (Hexatrione Dhcp 05 26 2026 Page 07)
Packaging label for Hexatrione 2%, triamcinolone hexacetonide injectable suspension, 40 mg/2 mL vial from Medexus Pharma, Inc. The label includes product name, strength, dosage form, route (intra-articular), usage instructions, inactive ingredients, storage instructions, and barcodes. The design features blue, white, and purple colors with the Medexus Pharma logo.*
FDA Label Image

Dhcp P8 (Hexatrione Dhcp 05 26 2026 Page 08)

Dhcp P8 (Hexatrione Dhcp 05 26 2026 Page 08)
Composition panel text for triamcinolone hexacetonide injection, showing each mL contains 20 mg of active ingredient. Inactive ingredients listed include polysorbate 80, sorbitol solution, water for injection, hydrochloric acid, sodium hydroxide for pH adjustment, and benzyl alcohol as preservative. The text emphasizes single use and precautions to keep out of reach of children.*
FDA Label Image

Dhcp P9 (Hexatrione Dhcp 05 26 2026 Page 09)

Dhcp P9 (Hexatrione Dhcp 05 26 2026 Page 09)
This label text panel for Aristospan (triamcinolone hexacetonide injectable suspension) 20 mg/mL parenteral displays warnings against use in newborns and intravenous administration, specifying intra-articular use only. It includes a description of the sterile suspension with inactive ingredients and a structural formula of the active ingredient. The panel also contains an introductory section on clinical pharmacology related to glucocorticoids.*
FDA Label Image

Dhcp P10 (Hexatrione Dhcp 05 26 2026 Page 10)

Dhcp P10 (Hexatrione Dhcp 05 26 2026 Page 10)
This text panel includes sections on the indications and usage, contraindications, and warnings for a corticosteroid injectable suspension, specifically triamcinolone hexacetonide. It mentions the intra-articular administration, hypersensitivity contraindications, and serious neurologic adverse reactions reported with epidural administration, as well as warnings about benzyl alcohol toxicity and rare anaphylactoid reactions.*
FDA Label Image

Dhcp P11 (Hexatrione Dhcp 05 26 2026 Page 11)

Dhcp P11 (Hexatrione Dhcp 05 26 2026 Page 11)
This text panel covers precautions related to corticosteroid therapy, including increased dosage during stress, cardiovascular and renal effects, endocrine impact, immunosuppression, and infection risks. It discusses the effects on blood pressure, potassium excretion, hypothalamic-pituitary-adrenal axis suppression, and advises caution with drug interactions and monitoring for infections.*
FDA Label Image

Dhcp P12 (Hexatrione Dhcp 05 26 2026 Page 12)

Dhcp P12 (Hexatrione Dhcp 05 26 2026 Page 12)
This is a text panel discussing safety warnings related to ARISTOSPAN, a corticosteroid drug. It covers various infection risks including tuberculosis, varicella zoster, measles, hepatitis B virus reactivation, fungal infections, amebiasis, and Strongyloides infestation. Each section advises caution and monitoring in patients receiving corticosteroid therapy. The text emphasizes the need for screening, prophylaxis, and expert consultation when necessary.*
FDA Label Image

Dhcp P13 (Hexatrione Dhcp 05 26 2026 Page 13)

Dhcp P13 (Hexatrione Dhcp 05 26 2026 Page 13)
A text panel containing drug precaution information related to corticosteroids, covering topics such as cerebral malaria, vaccination guidelines, neurologic and ophthalmic effects, Kaposi's sarcoma, and general precautions. The text advises avoiding corticosteroids in cerebral malaria, contraindications for live vaccines, risks of intrathecal administration, ocular side effects, and cautions about treatment dose and duration.*
FDA Label Image

Dhcp P14 (Hexatrione Dhcp 05 26 2026 Page 14)

Dhcp P14 (Hexatrione Dhcp 05 26 2026 Page 14)
Text from the Hexatrione 2% (triamcinolone hexacetonide) intra-articular injection label discusses cardiac, renal, endocrine, gastrointestinal, intra-articular, and musculoskeletal considerations. It covers warnings about sodium retention, adrenocortical insufficiency, steroid use caution in gastrointestinal conditions, risks with intra-articular injections, and effects on bone formation and resorption.*
FDA Label Image

Dhcp P15 (Hexatrione Dhcp 05 26 2026 Page 15)

Dhcp P15 (Hexatrione Dhcp 05 26 2026 Page 15)
This text panel provides information on neuro-psychiatric effects, ophthalmic considerations, patient information, and drug interactions related to corticosteroid use. It covers topics such as risks of acute myopathy, psychic derangements, intraocular pressure monitoring, patient warnings on corticosteroid use and infection risks, and specific drug interactions with aminoglutethimide and amphotericin B.*
FDA Label Image

Dhcp P16 (Hexatrione Dhcp 05 26 2026 Page 16)

Dhcp P16 (Hexatrione Dhcp 05 26 2026 Page 16)
A section of a drug facts or prescribing information text panel describing drug interactions with corticosteroids. It includes information on macrolide antibiotics, anticholinesterases, oral anticoagulants, antidiabetics, antitubercular drugs, cholestyramine, cyclosporine, digitalis glycosides, estrogens including oral contraceptives, hepatic enzyme inducers like barbiturates, phenytoin, carbamazepine, rifampin, and ketoconazole. The text discusses effects on corticosteroid metabolism and potential risks when used concurrently.*
FDA Label Image

Dhcp P17 (Hexatrione Dhcp 05 26 2026 Page 17)

Dhcp P17 (Hexatrione Dhcp 05 26 2026 Page 17)
This text panel covers warnings and precautions for corticosteroids, including increased gastrointestinal risks when combined with NSAIDs, suppression of skin test reactions, diminished vaccine response, and potential carcinogenesis and fertility impairment. It addresses pregnancy risks, nursing considerations, and pediatric warnings regarding benzyl alcohol, highlighting safety concerns and monitoring recommendations.*
FDA Label Image

Dhcp P18 (Hexatrione Dhcp 05 26 2026 Page 18)

Dhcp P18 (Hexatrione Dhcp 05 26 2026 Page 18)
This text panel discusses pediatric and geriatric use of corticosteroids, including potential adverse effects such as toxicity related to benzyl alcohol, efficacy in pediatric populations, and monitoring considerations for growth and systemic exposure. It also briefly introduces adverse reactions like anaphylactoid reactions, anaphylaxis, and angioedema.*
FDA Label Image

Dhcp P19 (Hexatrione Dhcp 05 26 2026 Page 19)

Dhcp P19 (Hexatrione Dhcp 05 26 2026 Page 19)
This image shows a text panel listing adverse reactions categorized by body system, including Cardiovascular, Dermatologic, Endocrine, Fluid and Electrolyte Disturbances, Gastrointestinal, Metabolic, Musculoskeletal, and Neurologic/Psychiatric disorders. Examples include bradycardia, acne, decreased carbohydrate tolerance, fluid retention, abdominal distention, negative nitrogen balance, aseptic necrosis, and convulsions, among others.*
FDA Label Image

Dhcp P20 (Hexatrione Dhcp 05 26 2026 Page 20)

Dhcp P20 (Hexatrione Dhcp 05 26 2026 Page 20)
This text panel includes sections on Ophthalmic and Other side effects, Overdosage treatment, and Dosage and Administration guidelines for triamcinolone hexacetonide injectable suspension. It mentions specific adverse effects, overdose management, and general dosing instructions, including pediatric dosing variability and the need for gradual withdrawal after long-term therapy.*
FDA Label Image

Dhcp P21 (Hexatrione Dhcp 05 26 2026 Page 21)

Dhcp P21 (Hexatrione Dhcp 05 26 2026 Page 21)
This image displays part of a drug instruction and dosage text panel. It includes dose equivalence values for various corticosteroids, directions for use emphasizing aseptic technique and suspension agitation, dilution recommendations, intra-articular dosing guidelines, and information on product supply for Aristospan (triamcinolone hexacetonide injectable suspension). The text also mentions considerations for needle size, local anesthetics, and injection frequency.*
FDA Label Image

Dhcp P22 (Hexatrione Dhcp 05 26 2026 Page 22)

Dhcp P22 (Hexatrione Dhcp 05 26 2026 Page 22)
A drug facts or storage instruction panel stating to store at 20°-25°C (68°-77°F), protect from light, and not to freeze the product. It also mentions distribution by Sandoz Inc., Princeton, NJ, and a revision date of 05/2024.*
FDA Label Image

Dhcp P23 (Hexatrione Dhcp 05 26 2026 Page 23)

Dhcp P23 (Hexatrione Dhcp 05 26 2026 Page 23)
This image shows the patient information leaflet and summary of product characteristics for Hexatrione 2% suspension for injection (Intra-Articular), containing triamcinolone hexacetonide. It includes sections on product composition, dosage form, clinical data, therapeutic indications, dosage and administration, warnings, precautions, contraindications, drug interactions, and special patient warnings. The document is intended for healthcare professionals and patients to inform on proper use and safety guidelines.*
FDA Label Image

Dhcp P24 (Hexatrione Dhcp 05 26 2026 Page 24)

Dhcp P24 (Hexatrione Dhcp 05 26 2026 Page 24)
Text panels showing detailed drug information for Hexatrione 2 percent injection, suspension (intra-articular) with triamcinolone hexacetonide. Includes sections on fertility, pregnancy, breastfeeding, undesirable effects with frequency tables, rare side effects, storage instructions, packaging contents, marketing authorization, and manufacturer details. The text provides safety, pharmacological, and handling information for healthcare professionals.*
FDA Label Image

Dhcp P25 (Hexatrione Dhcp 05 26 2026 Page 25)

Dhcp P25 (Hexatrione Dhcp 05 26 2026 Page 25)
Instructional text titled 'Instructions for Opening One Point Cut (OPC) Ampoules' explaining the safe method to open pre-scored OPC ampoules. It includes steps on preparing the work area and detailed guidance on how to open the ampoule without an ampoule opener, emphasizing safety and sterility precautions.*
FDA Label Image

Dhcp P26 (Hexatrione Dhcp 05 26 2026 Page 26)

Dhcp P26 (Hexatrione Dhcp 05 26 2026 Page 26)
Instructional diagram showing the step-by-step process for opening one point cut (OPC) ampoules with an ampoule opener, including safety tips to prevent glass shattering. The images depict holding the ampoule, positioning the opener, applying pressure, and safely breaking the ampoule neck with the colored dot as a reference.*
FDA Label Image

Dhcp P27 (Hexatrione Dhcp 05 26 2026 Page 27)

Dhcp P27 (Hexatrione Dhcp 05 26 2026 Page 27)
Text instructions on safe opening of pharmaceutical ampoules, emphasizing careful technique to avoid breakage and contamination. It advises not to force open ampoules and suggests using an ampoule opener or different ampoule if necessary. The text highlights that experience is essential for a clean break when opening ampoules and that operators develop their technique over time.*
FDA Label Image

Undefined (Hexatrione Ampoule 54002b)

Undefined (Hexatrione Ampoule 54002b)
Hexatrione 2 Percent injectable suspension label for intra-articular use containing triamcinolone hexacetonide. The label specifies a 2 mL glass ampoule with a concentration of 20 mg/mL. Warnings include respecting prescribed doses and use only under prescription. The label also shows lot number and expiration date, with Ethypharm as the labeler.*
FDA Label Image

Undefined (Hexatrion Carton 54002b)

Undefined (Hexatrion Carton 54002b)
Packaging label for Hexatrione 2% (triamcinolone hexacetonide) injectable suspension, intra-articular use, 40 mg/2 mL ampoule. The label indicates it is manufactured for Medexus Pharma, Inc. and by Laboratoires ETHYPHARM, France. The carton contains one 2 mL ampoule and provides storage, usage, and ingredient information including benzyl alcohol as a preservative.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.